ArticleBreast cancer research : BCR2025
Systemic glucocorticoids and the risk of breast cancer in a large nationwide case-control study.
Article in Breast cancer research : BCR, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Malignancies in lupus nephritis: a retrospective cohort study on epidemiology and risk factors.Lupus science & medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundConcerns have been raised that long-term use of glucocorticoids may increase the risk of breast cancer, yet evidence is limited. Thus, this study investigated the association between systemic glucocorticoid use and breast cancer risk, overall and by breast cancer subtype and stage.
methodsA nationwide case-control study was conducted using the Danish healthcare registries. Women with invasive breast cancer between 2001 and 2018 (n = 67,829) were identified as cases. Each case was matched to 10 population controls on age and calendar time. Ever users of glucocorticoids were defined as women who filled at least 2 prescriptions and long-term users those who filled prescriptions equivalent to ≥ 1000 defined daily doses (DDDs). Conditional logistic regressions were performed to calculate odds ratios (ORs) and 95% confidence intervals for the associations between glucocorticoid use and breast cancer risk.
resultsTwelve percent of women (n = 87,277) had ever been exposed to glucocorticoids and fewer than 1% were long-term users (n = 5,574). No association was found between ever use of glucocorticoids and breast cancer risk [OR = 1.00 (0.98-1.03)], compared with never use. However, an inverse association was observed between long-term glucocorticoid use and breast cancer risk [OR = 0.87 (0.77-0.97)], with suggestion of a slight dose-response relationship [OR per 500 DDDs = 0.96 (0.94-0.99)]. The associations were consistent across different tumour subtypes, estrogen receptor status, or clinical stage at diagnosis.
conclusionThe findings from this large nationwide study did not suggest a positive association between glucocorticoids and breast cancer risk.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.